바이오의약품 수탁제조 시장 규모, 점유율, 동향 분석 보고서 : 공급업체별, 서비스별, 의약품 종류별, 유형별, 사업 규모별, 치료 분야별, 지역별, 부문별 예측(2025-2030년)

Biopharmaceuticals Contract Manufacturing Market Growth & Trends:

The global biopharmaceuticals contract manufacturing market size is estimated to reach USD 75.80 billion by 2030, expanding at a CAGR of 11.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet the companies' demands with respect to regulatory standards and new services. The pandemic has, however, also had some negative knock-on effects as budgets and resources are diverted to "COVID products" at the expense of other biologics projects in development for other therapeutic areas.

The reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise during the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio. The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca's COVID-19 vaccine candidate, AZD1222.

The future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

Biopharmaceuticals Contract Manufacturing Market Report Highlights:

• Mammalian-based biopharmaceutical contract manufacturing captured the largest market share about 57.1% in 2024 owing to the high penetration of mammalian expression systems for biologics development
• Process development services held the largest revenue share in the global market in 2024., owing to high capital investment, especially in downstream process
• Biologics contract manufacturing dominated its counterpart segment owing to higher demand for biologics production. However, The biosimilar segment is anticipated to register the fastest CAGR over the forecast period due to cost-saving advantages associated with biosimilars development
• The presence of an effective regulatory framework for biologics development in the U.S. has resulted in a large share of the North America market of 34.3% in 2024
• Asia Pacific biopharmaceuticals contract manufacturing market is growing at a lucrative pace and is expected to emerge as the fastest-growing geographical area for biopharmaceutical R&D and manufacturing owing to developing economies such as India and China incorporating developments to sustain the competition

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceuticals Contract Manufacturing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rise in investment by CMOs for capacity expansion
    • 3.2.1.2. Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals
    • 3.2.1.3. Notable growth of biologics approvals
    • 3.2.1.4. Robust biopharmaceuticals pipeline
    • 3.2.1.5. Cost and time-saving benefits offered by contract services
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Limited outsourcing amongst well-established biopharmaceutical manufacturer
    • 3.2.2.2. Managing Relationships
• 3.3. Product Pipeline Analysis
• 3.4. Pricing Model Analysis
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL Analysis

Chapter 4. Biopharmaceuticals Contract Manufacturing Market: Source Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Source Movement Analysis
• 4.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Source, 2018-2030 (USD Million)
• 4.4. Mammalian
  • 4.4.1. Mammalian Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Non-mammalian
  • 4.5.1. Non-mammalian Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Biopharmaceuticals Contract Manufacturing Market: Service Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Service Movement Analysis
• 5.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Service, 2018-2030 (USD Million)
• 5.4. Process Development
  • 5.4.1. Process Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Downstream Processing
    • 5.4.2.1. Downstream Processing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Upstream Processing
    • 5.4.3.1. Upstream Processing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Fill & Finish Operations
  • 5.5.1. Fill & Finish Operations Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Analytical & QC Studies
  • 5.6.1. Analytical & QC Studies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Packaging & Labelling
  • 5.7.1. Packaging & Labelling Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Biopharmaceuticals Contract Manufacturing Market: Drug Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Drug Type Movement Analysis
• 6.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Drug Type, 2018-2030 (USD Million)
• 6.4. Biologics
  • 6.4.1. Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. Monoclonal Antibodies
    • 6.4.2.1. Monoclonal Antibodies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Recombinant proteins
    • 6.4.3.1. Recombinant Proteins Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Vaccines
    • 6.4.4.1. Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.5. Antisense, RNAi, & Molecular Therapy
    • 6.4.5.1. Antisense, RNAi, & Molecular Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Biosimilar
  • 6.5.1. Biosimilar Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Biopharmaceuticals Contract Manufacturing Market: Type Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Type Movement Analysis
• 7.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Type, 2018-2030 (USD Million)
• 7.4. Drug Substance
  • 7.4.1. Drug Substance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Finished Drug Product
  • 7.5.1. Finished Drug Product Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Biopharmaceuticals Contract Manufacturing Market: Scale of Operation Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Scale of Operation Movement Analysis
• 8.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Scale of Operation, 2018-2030 (USD Million)
• 8.4. Clinical
  • 8.4.1. Clinical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Commercial
  • 8.5.1. Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis

• 9.1. Segment Dashboard
• 9.2. Therapeutic Area Movement Analysis
• 9.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Therapeutic Area, 2018-2030 (USD Million)
• 9.4. Oncology
  • 9.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.5. Autoimmune Diseases
  • 9.5.1. Autoimmune Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.6. Infectious Diseases
  • 9.6.1. Infectious Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.7. Cardiovascular Diseases
  • 9.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.8. Metabolic Diseases
  • 9.8.1. Metabolic Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.9. Neurology
  • 9.9.1. Neurology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.10. Others
  • 9.10.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Biopharmaceuticals Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 10.1. Regional market share analysis, 2024 & 2030
• 10.2. Regional Market Dashboard
• 10.3. North America
  • 10.3.1. North America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.3.2. U.S.
    • 10.3.2.1. Key Country Dynamics
    • 10.3.2.2. Competitive Scenario
    • 10.3.2.3. Regulatory Landscape
    • 10.3.2.4. U.S. Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.3.3. Canada
    • 10.3.3.1. Key Country Dynamics
    • 10.3.3.2. Competitive Scenario
    • 10.3.3.3. Regulatory Landscape
    • 10.3.3.4. Canada Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.3.4. Mexico
    • 10.3.4.1. Key Country Dynamics
    • 10.3.4.2. Competitive Scenario
    • 10.3.4.3. Regulatory Landscape
    • 10.3.4.4. Mexico Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 10.4. Europe
  • 10.4.1. Europe Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.2. U.K.
    • 10.4.2.1. Key Country Dynamics
    • 10.4.2.2. Competitive Scenario
    • 10.4.2.3. Regulatory Landscape
    • 10.4.2.4. U.K. Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.3. Germany
    • 10.4.3.1. Key Country Dynamics
    • 10.4.3.2. Competitive Scenario
    • 10.4.3.3. Regulatory Landscape
    • 10.4.3.4. Germany Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.4. France
    • 10.4.4.1. Key Country Dynamics
    • 10.4.4.2. Competitive Scenario
    • 10.4.4.3. Regulatory Landscape
    • 10.4.4.4. France Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.5. Italy
    • 10.4.5.1. Key Country Dynamics
    • 10.4.5.2. Competitive Scenario
    • 10.4.5.3. Regulatory Landscape
    • 10.4.5.4. Italy Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.6. Spain
    • 10.4.6.1. Key Country Dynamics
    • 10.4.6.2. Competitive Scenario
    • 10.4.6.3. Regulatory Landscape
    • 10.4.6.4. Spain Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.7. Denmark
    • 10.4.7.1. Key Country Dynamics
    • 10.4.7.2. Competitive Scenario
    • 10.4.7.3. Regulatory Landscape
    • 10.4.7.4. Denmark Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.8. Sweden
    • 10.4.8.1. Key Country Dynamics
    • 10.4.8.2. Competitive Scenario
    • 10.4.8.3. Regulatory Landscape
    • 10.4.8.4. Sweden Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.9. Norway
    • 10.4.9.1. Key Country Dynamics
    • 10.4.9.2. Competitive Scenario
    • 10.4.9.3. Regulatory Landscape
    • 10.4.9.4. Norway Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 10.5. Asia Pacific
  • 10.5.1. Asia Pacific Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5.2. China
    • 10.5.2.1. Key Country Dynamics
    • 10.5.2.2. Competitive Scenario
    • 10.5.2.3. Regulatory Landscape
    • 10.5.2.4. China Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5.3. Japan
    • 10.5.3.1. Key Country Dynamics
    • 10.5.3.2. Competitive Scenario
    • 10.5.3.3. Regulatory Landscape
    • 10.5.3.4. Japan Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5.4. India
    • 10.5.4.1. Key Country Dynamics
    • 10.5.4.2. Competitive Scenario
    • 10.5.4.3. Regulatory Landscape
    • 10.5.4.4. India Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5.5. South Korea
    • 10.5.5.1. Key Country Dynamics
    • 10.5.5.2. Competitive Scenario
    • 10.5.5.3. Regulatory Landscape
    • 10.5.5.4. South Korea Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5.6. Australia
    • 10.5.6.1. Key Country Dynamics
    • 10.5.6.2. Competitive Scenario
    • 10.5.6.3. Regulatory Landscape
    • 10.5.6.4. Australia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5.7. Thailand
    • 10.5.7.1. Key Country Dynamics
    • 10.5.7.2. Competitive Scenario
    • 10.5.7.3. Regulatory Landscape
    • 10.5.7.4. Thailand Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 10.6. Latin America
  • 10.6.1. Latin America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.6.2. Brazil
    • 10.6.2.1. Key Country Dynamics
    • 10.6.2.2. Competitive Scenario
    • 10.6.2.3. Regulatory Landscape
    • 10.6.2.4. Brazil Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.6.3. Argentina
    • 10.6.3.1. Key Country Dynamics
    • 10.6.3.2. Competitive Scenario
    • 10.6.3.3. Regulatory Landscape
    • 10.6.3.4. Argentina Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 10.7. Middle East and Africa
  • 10.7.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.7.2. Saudi Arabia
    • 10.7.2.1. Key Country Dynamics
    • 10.7.2.2. Competitive Scenario
    • 10.7.2.3. Regulatory Landscape
    • 10.7.2.4. Saudi Arabia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.7.3. UAE
    • 10.7.3.1. Key Country Dynamics
    • 10.7.3.2. Competitive Scenario
    • 10.7.3.3. Regulatory Landscape
    • 10.7.3.4. UAE Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.7.4. South Africa
    • 10.7.4.1. Key Country Dynamics
    • 10.7.4.2. Competitive Scenario
    • 10.7.4.3. Regulatory Landscape
    • 10.7.4.4. South Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.7.5. Kuwait
    • 10.7.5.1. Key Country Dynamics
    • 10.7.5.2. Competitive Scenario
    • 10.7.5.3. Regulatory Landscape
    • 10.7.5.4. Kuwait Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Company Categorization
  • 11.1.1. Market Leaders
  • 11.1.2. Emerging Players
• 11.2. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
• 11.3. Company Profiles
  • 11.3.1. Boehringer Ingelheim GmbH
    • 11.3.1.1. Participant's Overview
    • 11.3.1.2. Financial Performance
    • 11.3.1.3. Service Benchmarking
    • 11.3.1.4. Strategic Initiatives
  • 11.3.2. Lonza
    • 11.3.2.1. Participant's Overview
    • 11.3.2.2. Financial Performance
    • 11.3.2.3. Service Benchmarking
    • 11.3.2.4. Strategic Initiatives
  • 11.3.3. Inno Biologics Sdn Bhd
    • 11.3.3.1. Participant's Overview
    • 11.3.3.2. Financial Performance
    • 11.3.3.3. Service Benchmarking
    • 11.3.3.4. Strategic Initiatives
  • 11.3.4. Rentschler Biotechnologies GmbH
    • 11.3.4.1. Participant's Overview
    • 11.3.4.2. Financial Performance
    • 11.3.4.3. Service Benchmarking
    • 11.3.4.4. Strategic Initiatives
  • 11.3.5. JRS PHARMA
    • 11.3.5.1. Participant's Overview
    • 11.3.5.2. Financial Performance
    • 11.3.5.3. Service Benchmarking
    • 11.3.5.4. Strategic Initiatives
  • 11.3.6. AGC Biologics
    • 11.3.6.1. Participant's Overview
    • 11.3.6.2. Financial Performance
    • 11.3.6.3. Service Benchmarking
    • 11.3.6.4. Strategic Initiatives
  • 11.3.7. ProBioGen
    • 11.3.7.1. Participant's Overview
    • 11.3.7.2. Financial Performance
    • 11.3.7.3. Service Benchmarking
    • 11.3.7.4. Strategic Initiatives
  • 11.3.8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
    • 11.3.8.1. Participant's Overview
    • 11.3.8.2. Financial Performance
    • 11.3.8.3. Service Benchmarking
    • 11.3.8.4. Strategic Initiatives
  • 11.3.9. Toyobo Co. Ltd.
    • 11.3.9.1. Participant's Overview
    • 11.3.9.2. Financial Performance
    • 11.3.9.3. Service Benchmarking
    • 11.3.9.4. Strategic Initiatives
  • 11.3.10. Samsung Biologics
    • 11.3.10.1.1. Participant's Overview
    • 11.3.10.2. Financial Performance
    • 11.3.10.3. Service Benchmarking
    • 11.3.10.4. Strategic Initiatives
  • 11.3.11. Thermo Fisher Scientific, Inc.
    • 11.3.11.1. Participant's Overview
    • 11.3.11.2. Financial Performance
    • 11.3.11.3. Service Benchmarking
    • 11.3.11.4. Strategic Initiatives
  • 11.3.12. Binex Co., Ltd.
    • 11.3.12.1. Participant's Overview
    • 11.3.12.2. Financial Performance
    • 11.3.12.3. Service Benchmarking
    • 11.3.12.4. Strategic Initiatives
  • 11.3.13. WuXi Biologics
    • 11.3.13.1. Participant's Overview
    • 11.3.13.2. Financial Performance
    • 11.3.13.3. Service Benchmarking
    • 11.3.13.4. Strategic Initiatives
  • 11.3.14. AbbVie, Inc.
    • 11.3.14.1. Participant's Overview
    • 11.3.14.2. Financial Performance
    • 11.3.14.3. Service Benchmarking
    • 11.3.14.4. Strategic Initiatives
  • 11.3.15. ADMA Biologics, Inc.
    • 11.3.15.1. Participant's Overview
    • 11.3.15.2. Financial Performance
    • 11.3.15.3. Service Benchmarking
    • 11.3.15.4. Strategic Initiatives
  • 11.3.16. Catalent, Inc
    • 11.3.16.1. Participant's Overview
    • 11.3.16.2. Financial Performance
    • 11.3.16.3. Service Benchmarking
    • 11.3.16.4. Strategic Initiatives
  • 11.3.17. Cambrex Corporation
    • 11.3.17.1. Participant's Overview
    • 11.3.17.2. Financial Performance
    • 11.3.17.3. Service Benchmarking
    • 11.3.17.4. Strategic Initiatives
  • 11.3.18. Pfizer Inc.
    • 11.3.18.1. Participant's Overview
    • 11.3.18.2. Financial Performance
    • 11.3.18.3. Service Benchmarking
    • 11.3.18.4. Strategic Initiatives
  • 11.3.19. Siegfried Holding AG
    • 11.3.19.1. Participant's Overview
    • 11.3.19.2. Financial Performance
    • 11.3.19.3. Service Benchmarking
    • 11.3.19.4. Strategic Initiatives